Filing summary: Tekmira Pharmaceuticals Corporation
Entity and period: The supplied filing is Tekmira Pharmaceuticals Corporation’s Form 10-K for the fiscal year ended December 31, 2013, with fourth-quarter results included. It is not identified as an Arbutus Biopharma filing; investors should verify the issuer and filing before relying on this summary. Financial amounts below are in U.S. dollars unless noted. Tekmira’s functional currency remained the Canadian dollar, while it adopted the U.S. dollar as its reporting currency effective October 1, 2013.
Business context
Tekmira was a clinical-stage biotechnology company developing RNA interference (RNAi) therapeutics and licensing its lipid nanoparticle (LNP) drug-delivery technology. Its pipeline included oncology, antiviral and metabolic programs. It reported no commercial revenue from its own RNAi products; revenue came primarily from collaborations, government contracts, milestones and licensing royalties.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $15.46 million | $14.11 million |
| Operating expenses | $27.62 million | $27.05 million |
| Loss from operations | ($12.15 million) | ($12.94 million) |
| Net income (loss) | ($14.06 million) | $29.61 million |
| Operating cash flow | ($6.74 million) | $32.91 million |
| Cash and cash equivalents at year-end | $68.72 million | $47.02 million |
| Total assets | $71.72 million | $52.60 million |
| Total liabilities | $12.52 million | $11.68 million |
- Revenue increased about 10% year over year, while operating expenses rose about 2%. Research, development, collaborations and contract expenses increased to $21.46 million from $18.04 million; general and administrative expense declined to $5.55 million from $8.14 million, primarily reflecting lower litigation-related costs.
- The 2012 profit was exceptional, driven by a $65.0 million Alnylam settlement payment, partly offset by $18.7 million in legal fees. The 2013 net loss also included a $3.53 million non-cash loss from revaluing warrant liabilities and a $1.08 million foreign-exchange gain.
- FY 2013 revenue included $9.81 million from the U.S. Department of Defense (DoD), approximately 63% of total revenue, and a $5.0 million Alnylam milestone. Spectrum royalties on Marqibo were $39,581.
- Q4 2013 revenue was $7.53 million versus $3.81 million in Q4 2012; Q4 net loss was $2.60 million versus net income of $38.19 million. The quarter’s revenue included the $5.0 million Alnylam milestone.
- Cash from operations was negative in 2013, despite the year-end cash increase, which was supported by $32.0 million net proceeds from an October 2013 share offering. No material conventional interest-bearing debt is identified in the supplied filing text; reported liabilities included payables, deferred revenue and $5.38 million of warrant liabilities.
- Current assets were $70.34 million against current liabilities of $12.52 million. The company reported net liquidity (cash less payables and accrued liabilities) of $65.04 million. Management said available resources were sufficient for at least 12 months, including a subsequent March 2014 offering.
- The filing does not provide a clear gross-margin measure; reported operating costs include substantial research and development and collaboration expenses.
Material changes and developments
- Tekmira resumed investment in earlier-stage research and expanded work on TKM-PLK1, TKM-HBV and TKM-ALDH2. Research and development spending rose as clinical and preclinical activity increased.
- The DoD increased targeted stage-one funding for TKM-Ebola from $34.7 million to $41.7 million. The broader program could receive up to approximately $140 million if extended, but future funding is subject to DoD decisions and contract performance.
- The TKM-Ebola Phase I study began in January 2014. The company also reported FDA Fast Track designation in March 2014 and was pursuing development under the Animal Rule, which depends substantially on animal efficacy evidence.
- In January 2014, Tekmira signed option and services agreements with Monsanto for agricultural applications of its delivery technology. Potential transaction value was stated as up to $86.2 million subject to milestones; $14.5 million of anticipated near-term payments had been received in January.
- In March 2014, Tekmira completed a public offering of 2.125 million shares at $28.50 per share, for estimated net proceeds of $56.6 million, before any over-allotment exercise. This is a subsequent event, not cash included in the December 31, 2013 balance sheet.
- Marqibo’s U.S. commercial launch began in September 2013 through licensee Spectrum. Tekmira is entitled to mid-single-digit royalties; meaningful commercial revenue had not yet been established.
Outlook, risks and contingencies
- Management expected interim TKM-PLK1 Phase I/II data in the second half of 2014 and planned a separate HCC study. It targeted an IND filing for TKM-HBV in the second half of 2014, with initial data expected in 2015, and aimed to prepare TKM-ALDH2 for an IND filing in the second half of 2014. These are forward-looking plans, not assured outcomes.
- The company expected to identify another development candidate in 2014. No quantitative revenue, earnings or cash-burn guidance was provided.
- Tekmira depended on a limited number of collaborators and funders; the DoD generated 63% of FY 2013 operating revenue. Revenue and cash receipts could vary with contract work, milestones, royalties and partner decisions.
- The company had accumulated a $167.0 million deficit and expected losses to continue. It stated that substantial additional capital would be needed over the coming years; inadequate funding could force delays, reductions or termination of programs.
- Clinical, regulatory, manufacturing and intellectual-property risks are significant. RNAi therapeutics were unapproved, and the Animal Rule pathway for TKM-Ebola was described as new and seldom used. The company also relied on third parties for clinical trials and future commercial manufacturing.
- Tekmira was in arbitration with Alnylam over a disputed $5.0 million milestone associated with an ALN-VSP technology transfer. No revenue was recorded for that claim. The company also reported ordinary-course legal matters that it did not expect to materially affect its financial position or results.
- Warrant-liability valuation is sensitive to share price and assumptions. A share-price increase contributed to the 2013 non-cash warrant revaluation loss. Foreign-currency movements also affected reported results and equity.
- Management assessed internal control over financial reporting as effective at year-end; the independent auditor did not provide an internal-control attestation because Tekmira was a non-accelerated filer.
Important facts for investors to verify
- Confirm that this Tekmira 2013 Form 10-K is the intended filing; the request names Arbutus Biopharma.
- Check the status and terms of the DoD TKM-Ebola contract, including actual reimbursements, remaining stage-one funding and any extension toward the potential $140 million program total.
- Review arbitration developments and whether the disputed Alnylam $5.0 million milestone was ultimately awarded or collected.
- Track cash burn, program spending and runway after the March 2014 offering, accounting for share issuance and possible further financing needs.
- Assess clinical-trial progress and data for TKM-PLK1, TKM-HBV, TKM-Ebola and TKM-ALDH2 against the filing’s stated timelines.
- Verify Monsanto payments actually received and the conditions, milestones and termination rights associated with the stated potential $86.2 million value.
- Monitor Marqibo sales and royalties, as FY 2013 royalty revenue was only $39,581 and the filing provides no established commercial-sales trend.